Bruised by a pun­ish­ing Op­di­vo fail­ure, Bris­tol-My­ers looks to shake up the busi­ness, ac­cel­er­ate R&D

Fresh off one of the biggest clin­i­cal tri­al set­backs of the year, Bris­tol-My­ers Squibb $BMY is plan­ning to re­group and ac­cel­er­ate on the R&D side as part of a broad re­or­ga­ni­za­tion, shift­ing more mon­ey in­to re­search af­ter hunt­ing out sav­ings in the rest of the busi­ness.

The de­tails are sparse, but the com­pa­ny says in its new­ly re­leased Q3 up­date that it plans to cre­ate a “com­pet­i­tive and more ag­ile R&D or­ga­ni­za­tion that can ac­cel­er­ate the pipeline, stream­lined op­er­a­tions and re­aligned man­u­fac­tur­ing ca­pa­bil­i­ties that broad­en bi­o­log­ics ca­pa­bil­i­ties to re­flect cur­rent and fu­ture port­fo­lio. The new op­er­at­ing mod­el will en­able the com­pa­ny to de­liv­er the strate­gic, fi­nan­cial and op­er­a­tional flex­i­bil­i­ty nec­es­sary to in­vest in the high­est pri­or­i­ties across the com­pa­ny.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER